Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab deruxtecan (Enhertu) for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
This is written in the approval document as:
As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
Citation
Trastuzumab Deruxtecan (Enhertu) Therapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 19/08/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/776-trastuzumab-deruxtecan-enhertu-therapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Trastuzumab deruxtecan |